Xenon Pharmaceuticals (XENE) Total Current Liabilities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Total Current Liabilities data on file, last reported at $39.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 24.31% year-over-year to $39.8 million in Q1 2026; TTM through Mar 2026 was $39.8 million, a 24.31% increase from a year earlier, with the FY2025 full-year figure at $41.8 million, up 17.43% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $39.8 million, down from $41.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for XENE reached as high as $41.8 million in Q4 2025 and fell as low as $8.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $27.4 million across 5 years, with a median of $28.2 million in 2023.
• Across the five-year window, Total Current Liabilities tumbled 30.54% in 2022 and jumped 181.77% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $22.7 million in 2022, then rose by 20.13% to $27.3 million in 2023, then soared by 30.5% to $35.6 million in 2024, then increased by 17.43% to $41.8 million in 2025, then decreased by 4.73% to $39.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $39.8 million in Q1 2026, $41.8 million in Q4 2025, and $38.3 million in Q3 2025.